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Lessons from the European Union: The Need for a 
Post-Grant Mechanism for Third-Party Challenge 
to U.S. Patents 
Jordan K. Paradise* 
I. INTRODUCTION 
Over the past year and a half the European Patent Office 
(EPO) has revoked or significantly narrowed claims contained 
within four patents issued to an American biotechnology 
company.  The patents at issue claim mutations in BRCA1 and 
BRCA2 genes associated with breast and ovarian cancer, 
methods for utilizing those mutations in diagnosis, and specific 
diagnostic kits.1  The patents were originally granted to Myriad 
Genetics, Inc., a corporation located in Salt Lake City, Utah.  
Full shares in the existing BRCA1 and BRCA2 patents were 
sold and reassigned to the University of Utah Research 
Foundation in November 2004.2  While Myriad Genetics no 
                                                          
       ©    2005 Jordan K. Paradise. 
        *   Associate Director of Research & Education, University of Minnesota 
Law School, Consortium on Law and Values in Health, Environment & the 
Life Sciences and Joint Degree Program in Law, Health & the Life Sciences. 
 1. The patents are Method for Diagnosing a Predisposition for Breast 
and Ovarian Cancer, Eur. Patent No. EP0699754 (filed Nov. 8, 1995) (issued 
Jan. 10, 2001); 17q-Linked Breast and Ovarian Cancer Susceptibility Gene, 
Eur. Patent No. EP0705902 (filed Nov. 8, 1995) (issued Nov. 28, 2001); 
Mutations in the 17q-Linked Breast and Ovarian Cancer Susceptibility Gene, 
Eur. Patent No. EP0705903 (filed Nov. 8, 1995) (issued May 23, 2001); and 
Chromosome 13-linked Cancer Susceptibility Gene BRCA2, Eur. Patent No. 
EP0785216 (filed Dec. 17, 1996) (issued Jan. 8, 2003).  The most recent 
opposition determination was handed down by the EPO on June 29, 2005.  See 
Press Release, European Patent Office, Patent on “Breast Cancer Gene 2” 
Patent Maintained in Amended Form After Public Hearing (June 29, 2005) 
[hereinafter Patent on Breast Cancer Gene 2], http://www.european-patent-
office.org/news/pressrel/2005_06_29_e.htm. 
 2. See Press Release, Institut Curie, Assistance Publique-Hôpitaux de 
Paris & Institut Gustave-Roussy, Another Victory for Opponents of Patents 
Held by Myriad Genetics: European Patent Office Rejects the Essential Points 
of BRCA1 Gene Patents (Jan. 31, 2005) [hereinafter Another Victory],  
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longer owns the patents, the corporation has retained exclusive 
licensing rights.3  Various hospitals, research laboratories, 
researchers, scientists, physicians, patient organizations, and 
humanitarian nonprofit organizations across Europe mounted 
challenges to the patents through a legal opposition procedure 
set out in European patent law.4  Opponents argued that these 
four patents violated numerous patentability requirements of 
the EPO and interfered with public health and research 
activities in a manner explicitly prohibited by multilateral 
European treaties and patent law.5 
These recent legal decisions in Europe have serious 
implications for the United States because Myriad Genetics 
and hundreds or even thousands of other patent holders have 
laid claim to large tracts of human genetic material by securing 
U.S. patents.  As a policy, both the U.S. and European patent 
offices routinely grant patents that claim human genetic 
material, although it is still openly debated whether genetic 
material is even patentable subject matter under existing 
patent law.6  In addition to legal arguments that genetic 
material is not patentable, many also argue that as a policy 
matter genetic material should not be patentable because of the 
detrimental effect on health care and research.7  Due to this 
increasing uncertainty and unrest regarding the validity of 
patents covering genetic material, it is imperative that the 
                                                          
http://www.curie.fr/upload/presse/myriadpatents310105.pdf.  The patent 
EP0699754 was granted to both Myriad Genetics, Inc. and the U.S. 
Department of Health & Human Services.  The University of Utah Research 
Foundation and the U.S. Department of Health & Human Services filed a joint 
notice of appeal with the EPO against the May 2004 decision to revoke that 
patent in its entirety.  Id. 
 3. See id. 
 4. See Press Release, Institut Curie, European-Wide Opposition Against 
the Breast Cancer Patents (Sept. 26, 2002), 
http://www.curie.fr/upload/presse/europeanoppmyriad_sept02_gb.pdf. 
 5. See Press Release, Institut Curie, Against Myriad Genetics’ Monopoly 
on Tests for Predisposition to Breast and Ovarian Cancer, the Institute Curie 
Is Initiating an Opposition Procedure with the European Patent Office (Sept. 
12, 2001), http://www.curie.fr/upload/presse/myriadopposition6sept01_gb.pdf. 
 6. See Jordan Paradise, European Opposition to Exclusive Control over 
Predictive Breast Cancer Testing and the Inherent Implications for U.S. Patent 
Law and Public Policy: A Case Study of the Myriad Genetics’ BRCA Patent 
Controversy, 59 FOOD & DRUG L.J. 133, 133-34 (2004); see also Linda J. 
Demaine & Aaron Xavier Fellmeth, Reinventing the Double Helix: A Novel and 
Nonobvious Reconceptualization of the Biotechnology Patent, 55 STAN. L. REV. 
303, 370 (2002). 
 7. Id. at 147-50. 
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United States develop an opposition procedure that gives third 
parties the ability to mount substantive challenges to claims 
contained within issued patents.  Not only would such an 
opposition procedure necessarily expand society’s role in 
promoting innovative scientific advancements, it would also 
strengthen the patent system by submitting patents to review 
and potentially eliminating patents that do not measure up to 
federal patent law.  Additionally, an opposition procedure 
would serve as a check on individual patent examiner decisions 
and cut down on expensive civil litigation by providing an 
alternative forum for would-be patent infringers.  This Article 
will focus on the recent legal developments in Europe and 
suggest that they serve as a wake-up call for the creation of a 
similar procedure of post-grant review in the United States.  
While I will address the need for an opposition procedure in the 
United States through the lens of certain patents claiming 
genetic sequence information, this system of legal challenge 
would apply across all subject matters and fields of technology. 
II. CONTROVERSY OVER PATENTS CLAIMING 
MUTATIONS IN BRCA1 & BRCA2 
A. EUROPEAN PATENT LAW 
The authority and substantive grounds for filing a legal 
challenge with the EPO are found in the European Patent 
Convention (EPC)8 and Directive 98/44/EC of the European 
Parliament and Council of the European Union (Directive).9  
The EPC is a multilateral patent treaty among European 
Union member states and various other European nations.  It 
provides for a type of legal procedure called an “opposition” that 
allows third parties to challenge the validity of a granted 
patent within nine months of the date of issuance.10  The 
opponent must identify specific claims within the patent that 
he or she believes fail to meet patentability requirements that 
bear on the validity of an invention.11  After formal oppositions 
                                                          
 8. Convention on the Grant of European Patents (European Patent 
Convention), Oct. 5 1973, 1065 U.N.T.S. 255 [hereinafter EPC], available at 
http://www.european-patent-office.org/legal/epc/. 
 9. Council Directive 98/44, On the Legal Protection of Biotechnical 
Inventions, 1998 O.J. (L 213) 13 (EC) [hereinafter Directive]. 
 10. EPC, supra note 8, at arts. 99-123. 
 11. Id. at art. 100.  An opposition may only be filed on the grounds that: 
(a) the subject-matter of the European patent is not patentable within 
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are filed with the EPO, the Opposition Division (OD), 
consisting of a panel of three patent examiners, holds public 
hearings on the matter and renders a decision applying current 
law as set forth in the EPC.12  The EPC establishes basic 
requirements for patentability, including that the invention is 
novel, involves an inventive step, is susceptible of industrial 
application,13 and sufficiently discloses the invention so that it 
can be carried out by a person skilled in that art.14  Significant 
to the recent legal challenges, it also provides that “discoveries, 
scientific theories and mathematical methods” are not 
patentable subject matter,15 “diagnostic methods” performed on 
the human body are not inventions for purposes of 
patentability,16 and, as a policy determination, inventions 
contrary to public morality are not patentable.17 
The Directive was promulgated as a means to address legal 
protections specifically for biotechnological inventions.  It 
contains the same basic patentability requirements as the EPC 
and provides explicit applications of the EPC to 
biotechnological inventions.  For example, the Directive states 
that the simple discovery of one of the elements of the human 
body, which includes “the sequence or partial sequence of a 
gene,” does not qualify for patent protection;18 however, it may 
be patentable if the sequence is isolated from the human body 
or produced by means of a technical process and is adequately 
disclosed.19  The Directive also reiterates the morality provision 
                                                          
the terms of Articles 52 to 57; (b) the European patent does not 
disclose the invention in a manner sufficiently clear and complete for 
it to be carried out by a person skilled in the art; (c) the subject-
matter of the European patent extends beyond the content of the 
application as filed, or, if the patent was granted on a divisional 
application or on a new application filed in accordance with Article 
61, beyond the content of the earlier application as filed. 
Id. 
 12. Id.  at arts. 101-02. 
 13. Id. at art. 52(1) & 56.  As a comparison, this industrial application 
requirement is parallel to the U.S. utility requirement and inventive step is 
parallel to the U.S. nonobviousness requirement.  See U.S.C. §§ 101, 103 
(2000). 
 14. EPC, supra note 8, at art. 83. 
 15. Id. at art. 52(2(a)). 
 16. Id. at art. 52(4). 
 17. Id. at art. 53(a). 
 18. Directive, supra note 9, at art. 5(1). 
 19. Id. at art. 5(2). 
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contained within the EPC.20 
1. Opposition History 
The opposition to the first of the four patents issued by the 
EPO, EP0699754, was filed September 6, 2001, by the French 
Institut Curie, a cancer research center and hospital, and was 
widely supported by the public, including the French Ministers 
for Research and Health21 and the European Parliament.22  In 
early October 2001, the Assistance Publique-Hôpitaux de Paris, 
a publicly-owned hospital, and the Institut Gustave-Roussy, a 
nonprofit, private cancer treatment center, filed a formal 
statement of opposition with the EPO.23  An opposition was also 
filed at this time by the Belgian Human Genetics Society, 
Belgian and Dutch human genetics centers, and German, 
Dutch, and British genetics societies.24  On February 22, 2002, 
the Institut Curie, the Assistance Publique-Hôpitaux de Paris, 
and the Institut Gustave-Roussy filed a joint opposition to 
EP0705903.25  The Belgian Ministries of Health, Social Affairs, 
and Scientific Research, the Dutch Ministry of Health, the 
German league against cancer, and Greenpeace Germany also 
filed statements of opposition at that time.26 
Joint statements of opposition to patent EP0705902 were 
formally filed on August 27, 2002, by the Institut Curie, the 
Assistance Publique-Hôpitaux de Paris, and the Institut 
Gustave-Roussy.  At the same time, a joint opposition was filed 
by the Belgian Society of Human Genetics, the Belgian and 
Dutch human genetic centers, German, Dutch, Czech, 
Austrian, Swiss, British, and Finnish genetics societies, the 
Greek National Center for Scientific Research, the Swiss 
Institute for Applied Cancer Research, and patient associations 
in the Netherlands and Belgium.27  The Swiss Social Democrat 
                                                          
 20. Id. at art. 6(1). 
 21. See Press Release, Institut Curie, The Key Dates (Sept. 26, 2002) 
[hereinafter The Key Dates], http://www.curie.fr/upload/presse/keydates.pdf. 
 22. See id. 
 23. See id. 
 24. See id. 
 25. See id. 
 26. See id. 
 27. See The Key Dates, supra note 21; see also Press Release, Institut 
Curie, European-Wide Opposition Against the Breast Cancer Patents (Sept. 
26, 2002), 
http://www.curie.fr/upload/presse/europeanoppmyriad_sept02_gb.pdf. 
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Party, Greenpeace Germany, the Dutch and Austrian Health 
Ministers, and an individual German doctor also filed notices of 
opposition to EP0705902.28  Opponents to the fourth patent, 
EP0785216, included the Institut Curie, the Assistance 
Publique-Hôpitaux de Paris, the Institut Gustave-Roussy, the 
Belgian Society of Human Genetics, and sixteen additional 
organizations across Europe, most of which had also opposed 
the previous patents.29 
2. Opposition Decisions 
Following three separate opposition proceedings, one of the 
patents, EP0699754, has been revoked in its entirety,30 and 
three, EP0705902, EP0705903, and EP0785216, have been 
significantly limited in their scope through amendments and 
revocation of individual claims.31  The latest opposition 
procedures resulted in an amendment limiting EP0785216 to a 
single claim.32  To date, appeals have been filed for three of the 
four decisions.33 
a. EP0699754 
The first BRCA1 patent, EP0699754, was revoked in its 
entirety by the OD after two days of opposition procedures in 
Munich, Germany on May 17 and 18, 2004.34  The OD cited a 
number of grounds for the revocation, including improper 
extension of subject matter by amendment of claims,35 lack of 
                                                          
 28. See The Key Dates, supra note 21. 
 29. See European Patent Office, Oral Proceedings Before the Opposition 
Division, Application No. 96 309 211.9, Facts and Submissions, Sept. 12,  
2005. 
 30. See Press Release, Institut Curie, Assistance Publique-Hôpitaux de 
Paris & Institut Gustave-Roussy, The European Patent Office Has Revoked 
the Myriad Genetics Patent (May 21, 2004), 
http://www.curie.fr/upload/presse/190504_gb/pdf. 
 31. See Another Victory, supra note 2. 
 32. See Press Release, Institut Curie, Assistance Publique-Hôpitaux de 
Paris & Institut Gustave-Roussy, L’Office Européen maintient le brevet sur le 
gène BRCA2 rèduit à une mutation particuliére et sans effet bloquant sur 
l’activité des laboratoires européens (July 6, 2005), 
http://www.curie.fr/upload/presse/brca2-myriad-6-juil-05.pdf. 
 33. See EPC, supra note 8, at arts. 106-12.  These sections provide parties 
with the right to appeal a decision of the Opposition Division within two 
months of notification of the decision. 
 34. See Another Victory, supra note 2. 
 35. See EPC, supra note 8, at art. 123(2). 
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clarity and conciseness,36 insufficient disclosure,37 and lack of 
inventive step.38 
b. EP0705902 & EP0705903 
Between January 19 and 26, 2005, the OD heard the 
opposition to both patents relating to materials and diagnostic 
methods used to isolate and detect mutations in the human 
breast and ovarian cancer predisposing gene BRCA1.39  
EP0705902 claimed the isolated BRCA1 gene, the 
corresponding protein, and the use of the BRCA1 gene for 
therapeutic applications.40  The OD determined that the patent 
holder improperly extended the subject matter by amendment 
of claims after issuance of the patent.41  As a result, claims 
toward diagnostic methods, involving claims to the isolated 
BRCA1 gene as a chemical molecule, claims to the 
corresponding protein, claims to conceivable therapeutic 
applications in gene therapy, drug screening, and transgenic 
animals, and claims to diagnostic kits were held invalid.42  
Claims specifically drawn to the nucleic acid probe and to 
vectors containing BRCA1 sequences were upheld.43 
EP0705903 claimed a total of thirty-four mutations in the 
BRCA1 gene, each with the ability to be used to test for a 
predisposition to breast and/or ovarian cancer.44  The OD 
determined that there was improper extension of subject 
matter by amendment of claims45 and a lack of clarity and 
conciseness.46  After deliberation, the OD decided that the 
priority dates applicable to the claimed sequences resulted in 
considerable restriction of the patent’s scope and permitted 
only a single claim to the 185delAG mutation to remain.47  The 
EP0705903 patent now covers only a 15-30 nucleotide probe 
                                                          
 36. See id. at art. 84. 
 37. See id. at art. 83. 
 38. See id. at art. 56. 
 39. See Another Victory, supra note 2. 
 40. See id. 
 41. See EPC, supra note 8, at art. 123(2). 
 42. See Another Victory, supra note 2. 
 43. See id. 
 44. See id. 
 45. EPC, supra note 8, at art. 123(2). 
 46. See id. at art. 84. 
 47. See Another Victory, supra note 2. 
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framing the 185delAG mutation.48 
c. EP0785216 
On June 29, 2005, the OD determined that the amendment 
of claims contained within EP0785216 by the patent holder met 
the requirements of the EPC.49  However, as a result of the 
opposition proceedings, this patent was amended to contain a 
single claim over a nucleic acid sequence asserting a mutation 
of the BRCA2 gene associated with a predisposition to breast 
cancer for in vitro diagnosis of Ashkenazi Jewish women.50  
This amended claim has subsequently raised criticism from 
both the Ashkenazi Jewish community and the European 
Society of Human Genetics for specifically singling out an 
entire racial, ethnic, or familial group within a patent claim.51 
III. STATUS OF POST-GRANT OPPOSITION IN THE 
UNITED STATES 
In contrast to patent law in European nations, U.S. patent 
law does not provide a post-grant mechanism for third parties 
to challenge patents issued by the United States Patent and 
Trademark Office (USPTO), aside from the extremely narrow 
reexamination process.52  Reexamination allows a third party 
to file a request for the USPTO to review an issued patent, but 
reexamination is limited to grounds that prior art, consisting of 
patents or printed publications, exists that negates the 
patentability of the invention.53  It is not until the patent 
holder initiates an infringement lawsuit that questions 
regarding the validity of patent claims can be brought as a 
defense to the alleged infringement.54  As a consequence, a 
significant amount of insufficient or invalid patent claims may 
                                                          
 48. Id. 
 49. See Patent on Breast Cancer Gene 2, supra note 1. 
 50. See Another Victory, supra note 2. 
      51.  Nehama Abrahami Keighley, No Ashkenazi Gene, NEW SCIENTIST, 
July 23, 2005, at 21; Patent Singles Out Ashkenazi Jewish Women, NEW 
SCIENTIST, July 9, 2005, at 7; Press Release, European Society of Human 
Genetics, Geneticists Oppose Singling Out Jewish Women in European Breast 
Cancer Patent (June 15, 2005). 
 52. 35 U.S.C. §§ 301-307 (2000).  The Director of the USPTO on his or her 
own initiative may determine whether a substantial new question of 
patentability is raised.  35 U.S.C. § 303(a).  The determination will include an 
order for reexamination.  35 U.S.C. § 304. 
 53. 35 U.S.C. § 302. 
 54. 35 U.S.C. § 282(2)-(3) (2000). 
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stand despite the fact that they do not meet federal 
patentability requirements because questions of validity can 
only be raised as an affirmative defense and because the 
alleged infringer would rather pay licensing fees in order to 
avoid drawn-out, expensive litigation.55  The American 
Intellectual Property Law Association reports that these 
litigation costs can approach approximately $1.5 million per 
party.56 
Many argue that rapid increases in patent applications 
over the past decade have bombarded the USPTO, resulting in 
less scrutiny of applications and more patents being issued that 
are of low quality and questionable legal status.57  Since the 
middle of the 1980s, applications for utility patents at the 
USPTO have increased approximately 5% per year, from 
100,000 per year in 1970-1984 to nearly 330,000 per year in 
2001.58  The Organization for Economic Development and Co-
Operation reports that the difference between grant issuance 
rates for equivalent filing in the United States and Europe has 
increased from 18% to 40% in the past 20 years,59 meaning that 
the USPTO is issuing patents that would be rejected by the 
EPO. 
A number of recent reports published by both federal 
government agencies and professional groups advocate 
increased options for post-grant review.60  In its 2003 report, 
The 21st Century Strategic Plan, the USPTO declared that a 
major priority for the future is to “[m]ake patents more reliable 
by proposing amendments to patent laws to improve a post-
                                                          
 55. Bronwyn H. Hall & Dietmar Harhoff, Post-Grant Reviews in the U.S. 
Patent System—Design Choices and Expected Impact, 19 BERKELEY TECH. L.J. 
989, 993 (2004). 
 56. John H. Barton, Policy Forum, Intellectual Property Rights: Reforming 
the Patent System, SCIENCE,  Mar. 17, 2000, at 1933 (citing AMERICAN 
INTELLECTUAL PROP. LAW ASS’N, REPORT OF ECONOMIC SURVEY 1999 tbls.21 
& 22 (1999)).  These costs have undoubtedly increased in the last six years. 
 57. See id. at 1934. 
 58. See Hall & Harhoff, supra note 55, at 995. 
 59. See id. at 998. 
 60. See, e.g., USPTO, THE 21ST CENTURY STRATEGIC PLAN (2003), 
http://www.uspto.gov/web/offices/com/strat21/stratplan_03feb2003.pdf; 
FEDERAL TRADE COMM’N, TO PROMOTE INNOVATION: THE PROPER BALANCE OF 
COMPETITION AND PATENT LAW AND POLICY (2003), 
http://www.ftc.gov/os/2003/10/innovationrpt.pdf; NATIONAL RESEARCH 
COUNCIL OF THE NAT’L ACADS., A PATENT SYSTEM FOR THE 21ST CENTURY 
(Stephen A. Merrill, Richard C. Levin & Mark B. Myers eds., 2004). 
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grant review of patents.”61  The USPTO has also indicated that 
a post-grant procedure allowing the public to petition the 
USPTO to review patent claims would “expand the role of the 
USPTO in enhancing the integrity of the intellectual property 
system” and “help assure that those potentially affected by the 
economic burdens of patents with invalid claims can obtain 
prompt redress.”62  Likewise, the Federal Trade Commission 
(FTC) recommends that Congress enact such an administrative 
opposition process to allow for “meaningful challenges to patent 
validity short of federal court litigation.”63  The FTC 
recommendation underscores the view that the current 
presumption of a patent’s validity is inappropriate in light of 
inadequate USPTO funding and insufficient review time of 
applications by patent examiners.64  The National Research 
Council of the National Academies also advocates that 
Congress “should seriously consider legislation” creating an 
opposition procedure in the United States because the “speed, 
cost, and design details of this proceeding should make it an 
attractive alternative to litigation to determine patent validity 
and be fair to all parties.”65 
The lack of such a post-grant third-party challenge is 
problematic because it prevents the larger public from 
weighing in on the validity of subject matter claimed within a 
patent.  In many respects, it is the public that has information 
relevant to issues of prior art, especially in the scientific 
literature, basic research, or prior patents, that the patent 
examiners at the USPTO may not have the expertise to identify 
or effectively review while they are assessing a patent 
application.  Uncertainty regarding the validity of patents 
issued by the USPTO has a variety of negative effects, such as 
underinvestment in technology because of the presence of 
patents that may be invalid, abandonment of specific areas of 
research because of existing patents that may actually be 
invalid, increased research and health care costs because of 
licensing fees paid out to patent holders, and costly patent 
                                                          
 61. USPTO, supra note 60, at 11. 
 62. USPTO, POST-GRANT REVIEW OF PATENT CLAIMS, 
http://www.uspto.gov/web/offices/com/strat21/action/sr2.htm (last modified 
Nov. 23, 2003). 
 63. FEDERAL TRADE COMM’N, supra note 60, at 8. 
 64. Id. 
 65. NATIONAL RESEARCH COUNCIL OF THE NAT’L ACADS., supra note 60, at 
82. 
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litigation. 
As a means to address these concerns and to remedy the 
lack of post-grant challenge procedures, the Patent Reform Act 
of 2005 (H.R. 2795) was recently introduced in the House of 
Representatives.66  This bill is the follow-up to H.R. 5299, 
introduced in the previous congressional session.67  Among 
other things, H.R. 2795 calls for the establishment of an 
opposition procedure allowing third parties to initiate a legal 
challenge to a patent issued by the USPTO within nine months 
of its issuance on the grounds that it does not fulfill one or 
more requirements set out in existing U.S. patent law.68  The 
proposal would also allow the filing of an opposition request by 
an accused infringer within six months of receiving notification 
that the patent holder has filed claims for patent 
infringement.69  A request for opposition would be required to 
identify the claims alleged to be invalid and to identify the 
grounds on which opposition is based for each claim, including 
any of the requirements for patentability provided in 35 U.S.C. 
sections 101, 102, 103, 112, and 251(d).70  These are the 
substantive requirements of utility, novelty, nonobviousness, 
adequate specification of the invention, including a written 
description of the invention, proper enablement of the 
invention allowing a person skilled in the art to make and use 
the invention, definiteness of claims distinctly pointing out the 
invention, and best mode of constructing the invention as 
contemplated by the inventor at the time of filing.71 
The introduction of H.R. 2795 has been met largely with 
support from lawmakers and the legal field, although some 
individuals caution that the reform measure is getting rushed 
through Congress without attention to detail.72  One criticism 
of the bill focuses on the structure of the proceedings, in which 
three administrative patent judges would compose the panel 
determining patentability as laid out in the opposition 
request.73  The concern is that the success of such a procedure 
                                                          
 66. H.R. REP. NO. 109-2795 (2005). 
 67. H.R. REP. NO. 108-5299 (2004). 
 68. H.R. 2795, 109th Cong. § 9 (2005). 
 69. Id. 
 70. Id. 
 71. See 35 U.S.C. §§ 101, 102, 103, 112, 251(d) (2000). 
 72. Peter Geier, Lawmakers Seek Less Expensive Patent System, N.Y.L.J., 
Aug. 18, 2005, at 5. 
 73. H.R. 2795 § 9. 
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will rely solely on the extent to which individuals and 
corporations will trust the administrative law judges to fairly 
arbitrate the patentability matters in front of them and 
examine the issues rather than deferring to the patent 
examiners.74 
IV. CONCLUSION 
The recent legal challenges in Europe have intensified the 
focus on attempts in the United States to create a post-grant 
opposition procedure.  In response to growing domestic and 
international concerns with patents involving genetic material 
and general concern with utility patents, it is imperative that 
the United States adopt an opposition procedure comparable to 
the patent practices of other industrialized nations.  While the 
proposed legislation may need some adjustments, provisions for 
opposition procedures laid out in H.R. 2795 are long overdue 
and would be a welcome improvement to U.S. patent law. 
 
                                                          
 74. Geier, supra note 72, at 6. 
